A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia

Lalami, Yassine; Paesmans, Marianne; Aoun, Michel; Munoz-Bermeo, R.; Reuss, K; Cherifi, Soraya; Alexopoulos, Constantinos; Klastersky, Jean

doi:10.1007/s00520-004-0658-6

Cited by 25 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were reported in a more recent study, in which 48 patients with various tumors and having received different chemotherapies, and who all experienced an episode of febrile neutropenia during the first cycle, received prophylaxis with GCSF during a subsequent course of the same chemotherapy without reduction in the dose intensity; the frequency of febrile neutropenia was 2% (one out of 48 patients) [11].…”

Section: Secondary Prophylaxissupporting

confidence: 80%

Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?

Klastersky¹,

Awada²,

Aoun³

et al. 2009

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

Section: Secondary Prophylaxissupporting

confidence: 80%

Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?

Klastersky¹,

Awada²,

Aoun³

et al. 2009

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…Chemotherapy-induced (CIN) and febrile neutropenia (FN) are potentially life-threatening complications of myelosuppressive chemotherapy, may often require hospitalization, and may result in disruptions to the planned chemotherapy regimen [1][2][3][4][5]. Known risk factors for CIN/FN enable clinicians to risk-stratify patients and initiate prophylaxis with granulocyte colony-stimulating factors (GCSF) [1,3,[6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

Gascón

Aapro

Ludwig

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

Purpose The purpose of this study is to examine the realworld treatment patterns and outcomes of chemotherapyinduced (febrile) neutropenia (chemotherapy-induced (CIN)/ febrile neutropenia (FN)) prophylaxis with biosimilar filgrastim (Zarzio®). Methods MONITOR-GCSF is an international (12 countries), multi-center (140), prospective (max. six cycles), observational, open-label, pharmaco-epidemiologic study of cancer patients (n=1447) treated with myelosuppressive chemotherapy across a total of 6,213 cycles and receiving prophylaxis with Zarzio®. Data were analyzed using both the patient and cycle as unit of analysis. Results Most (72.3 %) received primary prophylaxis; dosed mainly (53.2 %) at 30 MIU but differentiated by weight, chemotoxicity, and tumor type; and mainly (53.2 %) initiated in the 24-72h post-chemotherapy window but differentiated by prophylaxis type, tumor type, and chemotoxicity and for modal/median duration of 5 days. Relative to European Organisation for Research and Treatment of Cancer (EORTC) guidelines, 56.6 % were correctly prophylacted, 17.4 % under-prophylacted, and 26.0 % over-prophylacted. The following incidence rates were recorded: CIN grade 4 13.2 % of patients and 3.9 % of cycles, FN 5.9 % of patients and 1.4 % of cycles, CIN/FN-related hospitalizations 6.1 % of patients and 1.5 % of cycles, CIN/FN-related chemotherapy disturbances 9.5 % of patients and 2.8 % of cycles, and composite outcomes index 22.3 % of patients and 6.7 % of cycles. Rates varied by type of prophylaxis and tumor, chemotoxicity, initiation day, and prophylaxis duration. There were 1834

show abstract

“…Other authors have suggested that the use of prophylactic G-CSF, antibiotics and pegfilgrastim for the secondary prevention of FN is extremely effective and allows the maintenance of chemotherapy dose intensity (Lalami et al, 2004;Jenkins et al, 2012). Based on these studies, We are cautiously considering using hematopoietic growth factors and advances in antibiotic therapy on docetaxel-Based Systemic Chemotherapy with CRPC in the next study.…”

Section: Discussionmentioning

confidence: 99%

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Kwon¹,

Oh²,

Lee³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The aim of this study was to determine predictive factors for neutropenia after docetaxel-based systemic chemotherapy in patients with castration-resistant prostate cancer (CRPC). The study included 40 Korean CRPC patients who were treated with several cycles of docetaxel plus prednisolone from May 2005 to May 2012. Patients were evaluated for neutropenia risk factors and for the incidence of neutropenia. In this study, nine out of forty patients (22.5%) developed neutropenia during the first cycle of docetaxel-based systemic chemotherapy. Four experienced grade 2, three grade 3, and one grade 4 neutropenia. Multivariate analysis showed that pretreatment white blood cell (WBC) count (p=0.042), pretreatment neutrophil count (p=0.015), pretreatment serum creatinine level (p=0.027), and pretreatment serum albumin level (p=0.017) were significant predictive factors for neutropenia. In conclusion, pretreatment WBC counts, neutrophil counts, serum creatinine levels, and serum albumin levels proved to be significant independent risk factors for the development of neutropenia induced by docetaxel-based systemic chemotherapy in patients with CRPC.

show abstract

A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia

Abstract: The use of G-CSF for the secondary prevention of FN is extremely effective and allows the maintenance of chemotherapy dose intensity. Our study showed that the addition of antibiotics does not seem to be required.

Cited by 25 publications

References 26 publications

Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?

Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About